In this study we used casual and 24-h blood pressure (BP) monitoring and Doppler
echocardiographic data to investigate the antihypertensive and hemodynamic effects of …

To evaluate the magnitude and duration of the antihypertensive effect of sustained release
(SRO) isradipine, 37 uncomplicated essential hypertensive patients (diastolic blood …

The antihypertensive efficacy of slow-release oral (SRO) isradipine was evaluated in 392
patients (mean age, 53±9 years) with mild-to-moderate essential hypertension (diastolic …

Twelve patients with essential hypertension were randomized in a double-blind cross-over
study to investigate the blood pressure BP-lowering activity of isradipine regular formulation …

The clinical efficacy and tolerability of isradipine was evaluated in 63 patients with mild-to-
moderate hypertension [supine systolic blood pressure (SBP)>= 160 mm Hg and diastolic …

The antihypertensive efficacy of sustained-release isradipine administered once daily
compared to the immediate-release formulation administered twice daily was assessed by …

A total of 190 patients (mean age 57 years; range 21 to 89 years), with a supine diastolic
blood pressure (sDBP) of 100 to 120 mm Hg after a 3-week placebo phase, entered a …

Isradipine, 2.5 mg twice daily and placebo were administered for 4 weeks to 11 untreated
essential hypertensives in a double-blind, random order, crossover study. At the end of each …

The antihypertensive efficacy of isradipine has been widely studied. In most studies,
however, blood pressure values were assessed by casual readings (CR) only. Furthermore …

Fifty consecutive black patients with very severe hypertension (sitting diastolic blood
pressure≥ 120 mm Hg and systolic≥ 210 mm Hg by the conventional cuff method) were …